Abstract
COVID-19 is a highly infective disease caused by a novel coronavirus first identified in Wuhan, China, in December 2019. It has now evolved into a pandemic affecting at least 216 countries. The precise incidence of stroke in COVID-19 patients is unknown but is thought to affect up to 5.7% of severely affected individuals.1 It is also being recognised as the first clinical presentation of COVID-19, especially in young patients.2,3 Although computed tomography (CT) is the first line imaging technique to assess patients presenting with acute stroke symptoms, many centres prefer to evaluate further with magnetic resonance imaging (MRI).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
